Pancreatic Cancer Drugs Global Market Report 2024
March 07, 2024 04:09 ET
|
Research and Markets
Dublin, March 07, 2024 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The pancreatic cancer drugs market size...
Lung Cancer Drugs Global Market Report 2024 - Regulatory Approvals and Increased Patient Awareness and Education Propel the Market
December 11, 2023 11:58 ET
|
Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Lung Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The lung cancer drugs market size has grown...
Global Lung Cancer Drugs Market (2021 to 2030) - Featuring Bristol-Myers Squibb, Merck & Co and F. Hoffmann-La Roche Among Others
December 21, 2021 04:33 ET
|
Research and Markets
Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Lung Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. This...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
October 14, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
February 19, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 19, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and...
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
December 16, 2013 09:15 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage...
FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next
September 09, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...
Stock Market Media Group Issues Nuvilex, Inc. Road to Phase III Clinical Trials Report
August 15, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 15, 2013) - Stock Market Media Group, a research and content development investor relations firm, issued its Third Quarter Update and the first installment of its...
Nuvilex, Inc. Acquisition Could Be Steal of the Century and Worth Billions
July 18, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 18, 2013) - In a recently announced acquisition deal, Nuvilex, Inc. (OTCQB: NVLX), pulled off what can only be described as the steal of the century. The company...